Gadolinium Presence in Rat Skin: Assessment of Histopathologic Changes Associated with Small Fiber Neuropathy.

Autor:	Boyken J; From the Department of MR and CT Contrast Media Research (J.B., J.L., G.J., T.F., H.P.) and Research and Pre-Clinical Statistics Group (H.F.U.), Bayer, Müllerstraße 178, 13353 Berlin, Germany; Department of In Vivo/Radioanalytics (A.T.) and Department of Bioanalytics LC-MS 3 & MALDI (U.T.), Bayer, Wuppertal, Germany; Department of Neuropharmacology, QPS Austria, Grambach, Austria (J.N., M.P.); and External Corporate Employment Resources, Bayer U.S., Whippany, NJ (T.B.)., Lohrke J; From the Department of MR and CT Contrast Media Research (J.B., J.L., G.J., T.F., H.P.) and Research and Pre-Clinical Statistics Group (H.F.U.), Bayer, Müllerstraße 178, 13353 Berlin, Germany; Department of In Vivo/Radioanalytics (A.T.) and Department of Bioanalytics LC-MS 3 & MALDI (U.T.), Bayer, Wuppertal, Germany; Department of Neuropharmacology, QPS Austria, Grambach, Austria (J.N., M.P.); and External Corporate Employment Resources, Bayer U.S., Whippany, NJ (T.B.)., Treu A; From the Department of MR and CT Contrast Media Research (J.B., J.L., G.J., T.F., H.P.) and Research and Pre-Clinical Statistics Group (H.F.U.), Bayer, Müllerstraße 178, 13353 Berlin, Germany; Department of In Vivo/Radioanalytics (A.T.) and Department of Bioanalytics LC-MS 3 & MALDI (U.T.), Bayer, Wuppertal, Germany; Department of Neuropharmacology, QPS Austria, Grambach, Austria (J.N., M.P.); and External Corporate Employment Resources, Bayer U.S., Whippany, NJ (T.B.)., Neddens J; From the Department of MR and CT Contrast Media Research (J.B., J.L., G.J., T.F., H.P.) and Research and Pre-Clinical Statistics Group (H.F.U.), Bayer, Müllerstraße 178, 13353 Berlin, Germany; Department of In Vivo/Radioanalytics (A.T.) and Department of Bioanalytics LC-MS 3 & MALDI (U.T.), Bayer, Wuppertal, Germany; Department of Neuropharmacology, QPS Austria, Grambach, Austria (J.N., M.P.); and External Corporate Employment Resources, Bayer U.S., Whippany, NJ (T.B.)., Jost G; From the Department of MR and CT Contrast Media Research (J.B., J.L., G.J., T.F., H.P.) and Research and Pre-Clinical Statistics Group (H.F.U.), Bayer, Müllerstraße 178, 13353 Berlin, Germany; Department of In Vivo/Radioanalytics (A.T.) and Department of Bioanalytics LC-MS 3 & MALDI (U.T.), Bayer, Wuppertal, Germany; Department of Neuropharmacology, QPS Austria, Grambach, Austria (J.N., M.P.); and External Corporate Employment Resources, Bayer U.S., Whippany, NJ (T.B.)., Ulbrich HF; From the Department of MR and CT Contrast Media Research (J.B., J.L., G.J., T.F., H.P.) and Research and Pre-Clinical Statistics Group (H.F.U.), Bayer, Müllerstraße 178, 13353 Berlin, Germany; Department of In Vivo/Radioanalytics (A.T.) and Department of Bioanalytics LC-MS 3 & MALDI (U.T.), Bayer, Wuppertal, Germany; Department of Neuropharmacology, QPS Austria, Grambach, Austria (J.N., M.P.); and External Corporate Employment Resources, Bayer U.S., Whippany, NJ (T.B.)., Balzer T; From the Department of MR and CT Contrast Media Research (J.B., J.L., G.J., T.F., H.P.) and Research and Pre-Clinical Statistics Group (H.F.U.), Bayer, Müllerstraße 178, 13353 Berlin, Germany; Department of In Vivo/Radioanalytics (A.T.) and Department of Bioanalytics LC-MS 3 & MALDI (U.T.), Bayer, Wuppertal, Germany; Department of Neuropharmacology, QPS Austria, Grambach, Austria (J.N., M.P.); and External Corporate Employment Resources, Bayer U.S., Whippany, NJ (T.B.)., Frenzel T; From the Department of MR and CT Contrast Media Research (J.B., J.L., G.J., T.F., H.P.) and Research and Pre-Clinical Statistics Group (H.F.U.), Bayer, Müllerstraße 178, 13353 Berlin, Germany; Department of In Vivo/Radioanalytics (A.T.) and Department of Bioanalytics LC-MS 3 & MALDI (U.T.), Bayer, Wuppertal, Germany; Department of Neuropharmacology, QPS Austria, Grambach, Austria (J.N., M.P.); and External Corporate Employment Resources, Bayer U.S., Whippany, NJ (T.B.)., Prokesch M; From the Department of MR and CT Contrast Media Research (J.B., J.L., G.J., T.F., H.P.) and Research and Pre-Clinical Statistics Group (H.F.U.), Bayer, Müllerstraße 178, 13353 Berlin, Germany; Department of In Vivo/Radioanalytics (A.T.) and Department of Bioanalytics LC-MS 3 & MALDI (U.T.), Bayer, Wuppertal, Germany; Department of Neuropharmacology, QPS Austria, Grambach, Austria (J.N., M.P.); and External Corporate Employment Resources, Bayer U.S., Whippany, NJ (T.B.)., Thuss U; From the Department of MR and CT Contrast Media Research (J.B., J.L., G.J., T.F., H.P.) and Research and Pre-Clinical Statistics Group (H.F.U.), Bayer, Müllerstraße 178, 13353 Berlin, Germany; Department of In Vivo/Radioanalytics (A.T.) and Department of Bioanalytics LC-MS 3 & MALDI (U.T.), Bayer, Wuppertal, Germany; Department of Neuropharmacology, QPS Austria, Grambach, Austria (J.N., M.P.); and External Corporate Employment Resources, Bayer U.S., Whippany, NJ (T.B.)., Pietsch H; From the Department of MR and CT Contrast Media Research (J.B., J.L., G.J., T.F., H.P.) and Research and Pre-Clinical Statistics Group (H.F.U.), Bayer, Müllerstraße 178, 13353 Berlin, Germany; Department of In Vivo/Radioanalytics (A.T.) and Department of Bioanalytics LC-MS 3 & MALDI (U.T.), Bayer, Wuppertal, Germany; Department of Neuropharmacology, QPS Austria, Grambach, Austria (J.N., M.P.); and External Corporate Employment Resources, Bayer U.S., Whippany, NJ (T.B.).
Jazyk:	angličtina
Zdroj:	Radiology [Radiology] 2024 Jan; Vol. 310 (1), pp. e231984.
DOI:	10.1148/radiol.231984
Abstrakt:	Background The presence of gadolinium traces in the skin after administration of gadolinium-based contrast agents (GBCAs) raised safety concerns regarding a potential association with small fiber neuropathy (SFN). Purpose To investigate signs of SFN in rat foot pads by quantification of the intraepidermal nerve fiber density (IENFD) after multiple GBCA administrations and to evaluate gadolinium concentration, chemical species, and clearance. Materials and Methods Fifty rats received eight intravenous injections of either gadodiamide, gadobutrol, gadoterate, gadoteridol (8 × 0.6 mmol per kilogram of body weight), or saline (1.2 mL per kilogram of body weight), within 2 weeks and were sacrificed 5 days or 5 weeks after the last injection. IENFD was determined with protein gene product (PGP) 9.5 immunofluorescent staining and blinded and automated image analysis. The gadolinium and GBCA concentrations were measured with inductively coupled plasma mass spectrometry (ICP-MS), laser ablation ICP-MS, and matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI). P values were calculated using linear contrasts of model analysis. Results The IENFD (measured as geometric mean [SD] and in number of nerve fibers per millimeter of epidermis) was not significantly altered after 5 days (saline, 8.4 [1.1]; gadobutrol, 9.7 [1.2]; gadoterate, 9.2 [1.2]; gadoteridol, 9.9 [1.3]; gadodiamide, 10.5 [1.2]) or 5 weeks (saline, 19.7 [1.4]; gadobutrol, 16.4 [1.6]; gadoterate, 14.3 [1.6]; gadoteridol, 22.2 [1.8]; gadodiamide, 17.9 [1.4]). Gadolinium skin concentrations were highest for gadodiamide after 5 days (16.0 nmol/g [1.1]) and 5 weeks (10.6 nmol/g [1.2], -33%). Macrocyclic agents were lower at 5 days (gadoteridol, 2.6 nmol/g [1.2]; gadobutrol, 2.7 nmol/g [1.1]; and gadoterate, 2.3 nmol/g [1.2]) and efficiently cleared after 5 weeks (gadoteridol, -95%; gadobutrol and gadoterate, -96%). The distribution of gadolinium and IENF did not visually overlap. For macrocyclic agents, gadolinium was found in sweat glands and confirmed to be intact chelate. Conclusion There were no signs of SFN in rat foot pads using multiple dosing regimens at two time points after administration of GBCAs. Macrocyclic GBCAs exhibited lower levels of gadolinium in the skin and were effectively eliminated within 5 weeks compared with linear gadodiamide, and intact macrocyclic GBCA was detected in sweat glands. © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Clement in this issue.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu